Sunday, 25 Oct 2026
Empowering Chinese Pharma’s Global Expansion
Contact US
Home
About US
Policy Hub
Categories
Drug
Company
Deals
Policy / Regulatory
Medical Device
R&D
Legal / IP
Digital
Privacy Policy
Contact US
My News
Cancer
Clinical trial approval / initiation
Product approvals
Clinical trial results
Finance
ADC / XDC
Finanical Reports
Biotech
Market approval filings
PD-1/L1
Read History
Search
Pages
Home
Blog Index
POLICY HUB
Contact Us
Personalized
Read History
Categories
Company
Drug
Policy / Regulatory
Medical Device
R&D
Digital
Legal / IP
Deals
Have an existing account?
Sign In
Follow US
Company
Drug
RemeGen Announces Positive Phase III Results for Telitacicept in SLE
February 6, 2025
Company
Drug
BeiGene’s Brukinsa Receives New EU and UK Indications for BTK Inhibitor
February 6, 2025
Company
Drug
Alphamab Oncology Doses First Patient in Phase I Study for JSKN003 in Australia
February 6, 2025
Company
Deals
Beijing Launches HIV Precision Medicine Standardization Project
February 6, 2025
Company
Deals
Fosun Pharma Signs Exclusive Licensing Deal for H008 with Carephar
February 6, 2025
Company
Deals
Suzhou Weiyou Gene Bio Raises Pre-Series A Funding for Gene Therapy Pipeline
February 6, 2025
Company
Medical Device
Lepu Medtech Receives Approval for Innovative Peripheral Cutting Balloon
February 6, 2025
Company
Deals
Lepu Medtech Prices GDR Offering for International Expansion
February 6, 2025
Company
Deals
Zhong’ao Biopharmaceutical Secures Series A Funding for Cancer and HPV-Related Disease R&D
February 6, 2025
Policy / Regulatory
NHSA Launches Expert Review for 2025 NRDL Update in China
February 6, 2025
Company
Drug
Daehwa Pharmaceutical Files NDA for Liporaxel in China for Gastric Cancer Treatment
February 6, 2025
Company
Drug
Antengene’s ATG-101 Receives Orphan Drug Designation for Pancreatic Cancer
February 6, 2025
1
2
…
7
8
9
10
11
…
19
20
Welcome to Fineline Cube!
Username or Email Address
Password
Remember me
Lost your password?
